ES3031633T3 - Annexin a1 n-terminal peptide formulations and methods - Google Patents
Annexin a1 n-terminal peptide formulations and methodsInfo
- Publication number
- ES3031633T3 ES3031633T3 ES21765917T ES21765917T ES3031633T3 ES 3031633 T3 ES3031633 T3 ES 3031633T3 ES 21765917 T ES21765917 T ES 21765917T ES 21765917 T ES21765917 T ES 21765917T ES 3031633 T3 ES3031633 T3 ES 3031633T3
- Authority
- ES
- Spain
- Prior art keywords
- annexin
- pharmaceutical formulation
- seq
- liquid pharmaceutical
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20192142 | 2020-08-21 | ||
| PCT/EP2021/073186 WO2022038281A1 (en) | 2020-08-21 | 2021-08-20 | Annexin a1 n-terminal peptide formulations and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3031633T3 true ES3031633T3 (en) | 2025-07-10 |
Family
ID=72193322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21765917T Active ES3031633T3 (en) | 2020-08-21 | 2021-08-20 | Annexin a1 n-terminal peptide formulations and methods |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20230295255A1 (cg-RX-API-DMAC10.html) |
| EP (3) | EP4595950A3 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023539476A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116323649A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021327733A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3192030A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES3031633T3 (cg-RX-API-DMAC10.html) |
| HU (1) | HUE071875T2 (cg-RX-API-DMAC10.html) |
| PL (1) | PL4200319T3 (cg-RX-API-DMAC10.html) |
| WO (2) | WO2022038258A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3031633T3 (en) * | 2020-08-21 | 2025-07-10 | Resother Pharma As | Annexin a1 n-terminal peptide formulations and methods |
| US20250345392A1 (en) | 2022-06-30 | 2025-11-13 | Resother Pharma A/S | Annexin a1 liquid pharmaceutical composition |
| EP4680262A1 (en) | 2023-03-13 | 2026-01-21 | Resother Pharma A/S | Annexin a1 delayed dosing |
| AU2024234229A1 (en) | 2023-03-13 | 2025-09-25 | Resother Pharma A/S | Annexin a1 administration regime |
| WO2025083394A1 (en) | 2023-10-16 | 2025-04-24 | Therakind Limited | Antimicrobial use of annexin a1 protein |
| WO2025083393A1 (en) | 2023-10-16 | 2025-04-24 | Therakind Limited | Antimicrobial use of peptides derived from annexin a1 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9283260B2 (en) * | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| BR112013032088B1 (pt) | 2011-06-15 | 2020-11-24 | Resother Pharma Aps | produtos farmacêuticos anti-inflamatórios |
| WO2013053888A1 (en) * | 2011-10-14 | 2013-04-18 | Baxter International Inc. | Protein purification by anion exchange chromatography |
| HUE052977T2 (hu) | 2014-04-22 | 2021-06-28 | Txp Pharma Gmbh | Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok) |
| CN110302176A (zh) * | 2019-06-25 | 2019-10-08 | 中国人民解放军陆军军医大学 | 一种抗炎多肽纳米药物及制备方法 |
| ES3031633T3 (en) * | 2020-08-21 | 2025-07-10 | Resother Pharma As | Annexin a1 n-terminal peptide formulations and methods |
| US20250345392A1 (en) * | 2022-06-30 | 2025-11-13 | Resother Pharma A/S | Annexin a1 liquid pharmaceutical composition |
-
2021
- 2021-08-20 ES ES21765917T patent/ES3031633T3/es active Active
- 2021-08-20 WO PCT/EP2021/073125 patent/WO2022038258A1/en not_active Ceased
- 2021-08-20 AU AU2021327733A patent/AU2021327733A1/en active Pending
- 2021-08-20 PL PL21765917.6T patent/PL4200319T3/pl unknown
- 2021-08-20 EP EP25169758.7A patent/EP4595950A3/en active Pending
- 2021-08-20 CN CN202180050871.2A patent/CN116323649A/zh active Pending
- 2021-08-20 US US18/041,727 patent/US20230295255A1/en active Pending
- 2021-08-20 CA CA3192030A patent/CA3192030A1/en active Pending
- 2021-08-20 US US18/041,729 patent/US20240041977A1/en active Pending
- 2021-08-20 HU HUE21765917A patent/HUE071875T2/hu unknown
- 2021-08-20 EP EP21765917.6A patent/EP4200319B1/en active Active
- 2021-08-20 JP JP2023512755A patent/JP2023539476A/ja active Pending
- 2021-08-20 WO PCT/EP2021/073186 patent/WO2022038281A1/en not_active Ceased
- 2021-08-20 EP EP21766151.1A patent/EP4200320A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4200319C0 (en) | 2025-04-16 |
| EP4200319B1 (en) | 2025-04-16 |
| AU2021327733A9 (en) | 2023-04-27 |
| CA3192030A1 (en) | 2022-02-24 |
| US20230295255A1 (en) | 2023-09-21 |
| EP4200319A1 (en) | 2023-06-28 |
| WO2022038258A1 (en) | 2022-02-24 |
| AU2021327733A1 (en) | 2023-04-20 |
| EP4595950A2 (en) | 2025-08-06 |
| JP2023539476A (ja) | 2023-09-14 |
| PL4200319T3 (pl) | 2025-08-18 |
| HUE071875T2 (hu) | 2025-09-28 |
| CN116323649A (zh) | 2023-06-23 |
| EP4595950A3 (en) | 2025-10-29 |
| EP4200320A1 (en) | 2023-06-28 |
| US20240041977A1 (en) | 2024-02-08 |
| WO2022038281A1 (en) | 2022-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4200319B1 (en) | Annexin a1 n-terminal peptide formulations and methods | |
| ES2618073T3 (es) | Análogos de insulina estabilizados frente a proteasas | |
| ES2344729T3 (es) | Interleuquina 2 estabilizada. | |
| RU2332229C2 (ru) | Способ введения молекул glp-1 | |
| CN1812808B (zh) | 稳定化的药物肽组合物 | |
| BRPI0410972B1 (pt) | Method for increasing the shelf life of a pharmaceutical composition, pharmaceutical composition, and method for treating hyperglycemia | |
| ES2794082T3 (es) | Uso de dímeros de IL-22 en la fabricación de medicamentos para tratar la pancreatitis | |
| NZ552558A (en) | Compositions for delivering peptide YY and PYY agonists | |
| JP6537504B2 (ja) | ヘプラペプチドの製剤 | |
| ES2712805T3 (es) | Productos farmacéuticos antiinflamatorios | |
| ES2679520T3 (es) | Formulaciones de moléculas del factor de liberación de hormonas del crecimiento (GRF) con estabilidad mejorada | |
| JP2023166014A (ja) | コラーゲン７組成物及びそれを用いる方法 | |
| ES3019509T3 (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| US20220241371A1 (en) | Peptide formulations and ophthalmic uses thereof | |
| EP2253326B1 (en) | Pharmaceutical composition for transnasal administration | |
| JP2023527441A (ja) | レナラーゼアゴニスト活性を有する安定なペプチド | |
| CN115605218B (zh) | 用于治疗大疱性表皮松解症的归巢肽引导的核心蛋白聚糖缀合物 | |
| JPWO2016080367A1 (ja) | 安定化されたペプチド組成物 | |
| RU2833459C2 (ru) | Составы аналогов глюкагоноподобного пептида-2 (glp-2) | |
| RU2855486C1 (ru) | Фармацевтическая композиция двойных агонистов glp-1/glp-2 | |
| WO2011004054A1 (es) | Uso de anhidrasa carbónica ii para la elaboración de un medicamento | |
| JP2001522814A (ja) | 増大されたｉｇｆ−ｉ溶解性を提供する組成物 | |
| KR20180122144A (ko) | 인슐린 비강 전달용 제제 |